AbbVie (ABBV)
(Delayed Data from NYSE)
$197.55 USD
+1.18 (0.60%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $197.40 -0.15 (-0.08%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
- YR Estimate
- 12/31/2023
- 12/31/2022
- 12/31/2021
- 12/31/2020
- 12/31/2019
- Revenue - Line of Business (LOBR)
- Net Revenue: Humira
- 14,404.00
- 21,237.00
- 20,694.00
- 19,832.00
- 19,169.00
- Revenue - Line of Business (LOBR)
- Net Revenue: Immunology: Skyrizi: Total
- 7,763.00
- 5,165.00
- 2,939.00
- 1,590.00
- 355.00
- Revenue - Line of Business (LOBR)
- Net Revenue: Rinvoq: Total
- 3,969.00
- 2,522.00
- 1,651.00
- 731.00
- 47.00
- Revenue - Line of Business (LOBR)
- Net Revenue: Imbruvica
- 3,596.00
- 4,568.00
- 5,408.00
- 5,314.00
- 4,674.00
- Revenue - Line of Business (LOBR)
- Net Revenue: Venclexta
- 2,288.00
- 2,009.00
- 1,820.00
- 1,337.00
- 792.00
- Revenue - Line of Business (LOBR)
- Net Revenue: Botox Cosmetic: Total
- 2,682.00
- 2,615.00
- 2,232.00
- 1,112.00
- --
- Revenue - Line of Business (LOBR)
- Net Revenue: Vraylar: Total
- 2,759.00
- 2,038.00
- 1,728.00
- 951.00
- --
- Revenue - Line of Business (LOBR)
- Net Revenue: Duodopa
- 468.00
- 458.00
- 511.00
- 494.00
- 461.00
- Revenue - Line of Business (LOBR)
- Net Revenue: Ubrelvy: Total
- 815.00
- 680.00
- 552.00
- 125.00
- --
- Revenue - Line of Business (LOBR)
- Net Revenue: Qulipta: Total
- 408.00
- 158.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Net Revenue: Restasis: Total
- 436.00
- 666.00
- 1,290.00
- 787.00
- --
- Revenue - Line of Business (LOBR)
- Net Revenue: Lumigan/Ganfort
- 432.00
- 514.00
- 579.00
- 378.00
- --
- Revenue - Line of Business (LOBR)
- Net Revenue: Alphagan/Combigan: Total
- 272.00
- 346.00
- 529.00
- 326.00
- --
- Revenue - Line of Business (LOBR)
- Net Revenue: Hematologic Oncology: Total
- 5,915.00
- 6,577.00
- 7,228.00
- 6,651.00
- --
- Revenue - Line of Business (LOBR)
- Net Revenue: Immunology: Total
- 26,136.00
- 28,924.00
- 25,284.00
- 22,153.00
- 19,571.00
- Revenue - Line of Business (LOBR)
- Net Revenue: Neuroscience: Total
- 7,717.00
- 6,528.00
- 5,927.00
- 3,496.00
- 461.00
- Revenue - Line of Business (LOBR)
- Net Revenue: Other Neuroscience: Total
- 276.00
- 475.00
- 685.00
- 539.00
- --
- Revenue - Line of Business (LOBR)
- Net Revenue: Other Aesthetics: Total
- 1,234.00
- 1,290.00
- 1,466.00
- 760.00
- --
- Revenue - Line of Business (LOBR)
- Net Revenue: Other Eye Care: Total
- 803.00
- 1,175.00
- 1,169.00
- 693.00
- --
- Revenue - Line of Business (LOBR)
- Net Revenue: Eye Care: Total
- 2,415.00
- 2,701.00
- 3,567.00
- 2,184.00
- --
- Revenue - Line of Business (LOBR)
- Net Revenue: Juvederm Collection: Total
- 1,378.00
- 1,428.00
- 1,535.00
- 718.00
- --
- Revenue - Line of Business (LOBR)
- Net Revenue: Botox Therapeutic: Total
- 2,991.00
- 2,719.00
- 2,451.00
- 1,387.00
- --
- Revenue - Line of Business (LOBR)
- Net Revenue: Mavyret
- 1,430.00
- 1,541.00
- 1,710.00
- 1,830.00
- 2,893.00
- Revenue - Line of Business (LOBR)
- Net Revenue: Aesthetics: Total
- 5,294.00
- 5,333.00
- 5,233.00
- 2,590.00
- --
- Revenue - Line of Business (LOBR)
- Net Revenue: Creon
- 1,268.00
- 1,278.00
- 1,191.00
- 1,114.00
- 1,041.00
- Revenue - Line of Business (LOBR)
- Net Revenue: Eye Care: Ozurdex: Total
- 472.00
- --
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Net Revenue: Other Key Products: Total
- 3,806.00
- 3,854.00
- 5,489.00
- --
- --
- Revenue - Line of Business (LOBR)
- Net Revenue: Linzess/Constella: Total
- 1,108.00
- 1,035.00
- 1,038.00
- 667.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Humira: US
- 12,160.00
- 18,619.00
- 17,330.00
- 16,112.00
- 14,864.00
- Revenue - Geographic (GEOR)
- Net Revenue: Humira: International
- 2,244.00
- 2,618.00
- 3,364.00
- 3,720.00
- 4,305.00
- Revenue - Geographic (GEOR)
- Net Revenue: Immunology: Skyrizi: US
- 6,753.00
- 4,484.00
- 2,486.00
- 1,385.00
- 311.00
- Revenue - Geographic (GEOR)
- Net Revenue: Immunology: Skyrizi: International
- 1,010.00
- 681.00
- 453.00
- 205.00
- 44.00
- Revenue - Geographic (GEOR)
- Net Revenue: Rinvoq: US
- 2,824.00
- 1,794.00
- 1,271.00
- 653.00
- 47.00
- Revenue - Geographic (GEOR)
- Net Revenue: Rinvoq: International
- 1,145.00
- 728.00
- 380.00
- 78.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Imbruvica: US
- 2,665.00
- 3,426.00
- 4,321.00
- 4,305.00
- 3,830.00
- Revenue - Geographic (GEOR)
- Net Revenue: Imbruvica: International
- 931.00
- 1,142.00
- 1,087.00
- 1,009.00
- 844.00
- Revenue - Geographic (GEOR)
- Net Revenue: Venclexta: US
- 1,087.00
- 1,009.00
- 934.00
- 804.00
- 521.00
- Revenue - Geographic (GEOR)
- Net Revenue: Venclexta: International
- 1,201.00
- 1,000.00
- 886.00
- 533.00
- 271.00
- Revenue - Geographic (GEOR)
- Net Revenue: Mavyret: International
- 771.00
- 786.00
- 956.00
- 1,045.00
- 1,420.00
- Revenue - Geographic (GEOR)
- Net Revenue: Immunology: Total US
- 21,737.00
- 24,897.00
- 21,087.00
- 18,150.00
- 15,222.00
- Revenue - Geographic (GEOR)
- Net Revenue: Immunology: Total International
- 4,399.00
- 4,027.00
- 4,197.00
- 4,003.00
- 4,349.00
- Revenue - Geographic (GEOR)
- Net Revenue: Hematologic Oncology: US
- 3,778.00
- 4,435.00
- 5,255.00
- 5,109.00
- 4,351.00
- Revenue - Geographic (GEOR)
- Net Revenue: Hematologic Oncology: International
- 2,137.00
- 2,142.00
- 1,973.00
- 1,542.00
- 1,115.00
- Revenue - Geographic (GEOR)
- Net Revenue: Neuroscience: U.S
- 6,790.00
- 5,681.00
- 5,061.00
- 2,862.00
- 97.00
- Revenue - Geographic (GEOR)
- Net Revenue: Neuroscience: International
- 927.00
- 847.00
- 866.00
- 634.00
- 364.00
- Revenue - Geographic (GEOR)
- Net Revenue: Other Neuroscience: U.S
- 254.00
- 456.00
- 667.00
- 528.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Other Neuroscience: International
- 22.00
- 19.00
- 18.00
- 11.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Other Aesthetics: U.S
- 1,060.00
- 1,122.00
- 1,268.00
- 666.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Other Aesthetics: International
- 174.00
- 168.00
- 198.00
- 94.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Aesthetics: U.S
- 3,249.00
- 3,324.00
- 3,350.00
- 1,671.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Aesthetics: International
- 2,045.00
- 2,009.00
- 1,883.00
- 919.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Other Eye Care: U.S
- 433.00
- 538.00
- 523.00
- 305.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Other Eye Care: International
- 370.00
- 637.00
- 646.00
- 388.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Eye Care: U.S
- 1,252.00
- 1,603.00
- 2,403.00
- 1,448.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Eye Care: International
- 1,163.00
- 1,098.00
- 1,164.00
- 736.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Ubrelvy: U.S
- 803.00
- 680.00
- 552.00
- 125.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Ubrelvy: International
- 12.00
- --
- 0.00
- 0.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Botox Cosmetic: US
- 1,670.00
- 1,654.00
- 1,424.00
- 687.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Botox Cosmetic: International
- 1,012.00
- 961.00
- 808.00
- 425.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Juvederm Collection: US
- 519.00
- 548.00
- 658.00
- 318.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Juvederm Collection: International
- 859.00
- 880.00
- 877.00
- 400.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Botox Therapeutic: US
- 2,476.00
- 2,255.00
- 2,012.00
- 1,155.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Botox Therapeutic: International
- 515.00
- 464.00
- 439.00
- 232.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Alphagan/Combigan: US
- 121.00
- 202.00
- 373.00
- 223.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Alphagan/Combigan: International
- 151.00
- 144.00
- 156.00
- 103.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Lumigan/Ganfort: US
- 173.00
- 242.00
- 273.00
- 165.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Lumigan/Ganfort: International
- 259.00
- 272.00
- 306.00
- 213.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Restasis: US
- 382.00
- 621.00
- 1,234.00
- 755.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Restasis: International
- 54.00
- 45.00
- 56.00
- 32.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Vraylar: US
- 2,755.00
- 2,037.00
- 1,728.00
- 951.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Vraylar: International
- 4.00
- 1.00
- 0.00
- 0.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Linzess/Constella: US
- 1,073.00
- 1,003.00
- 1,006.00
- 649.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Linzess/Constella: International
- 35.00
- 32.00
- 32.00
- 18.00
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Other Key Products: U.S
- 3,000.00
- 3,036.00
- 4,322.00
- --
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Other Key Products: International
- 806.00
- 818.00
- 1,167.00
- --
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Eye Care: Ozurdex: US
- 143.00
- --
- --
- --
- --
- Revenue - Geographic (GEOR)
- Net Revenue: Eye Care: Ozurdex: ROW
- 329.00
- --
- --
- --
- --
- Revenue - Geographic (GEOR)
- Geographic Revenues: United States
- 41,883.00
- 45,713.00
- 43,510.00
- 34,879.00
- 23,907.00
- Revenue - Geographic (GEOR)
- Net Revenue: Creon: US
- 1,268.00
- 1,278.00
- 1,191.00
- 1,114.00
- 1,041.00
- Revenue - Geographic (GEOR)
- Net Revenue: Duodopa: International
- 371.00
- 363.00
- 409.00
- 391.00
- 364.00
- Revenue - Geographic (GEOR)
- Net Revenue: Duodopa: US
- 97.00
- 95.00
- 102.00
- 103.00
- 97.00
- Revenue - Geographic (GEOR)
- Geographic Revenues: International
- 12,435.00
- 12,341.00
- --
- 10,925.00
- 9,359.00
- Revenue - Geographic (GEOR)
- Net Revenue: Mavyret: US
- 659.00
- 755.00
- 754.00
- 785.00
- 1,473.00